Media Scrutiny: How News Reports Frame Semaglutide's Link to Eye Condition NAION

As Semaglutide, a widely prescribed GLP-1 receptor agonist, gains prominence for managing type 2 diabetes and obesity, its increasing use has drawn significant public and media attention, including reports of potential adverse events. One such concern involves Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), a serious condition causing sudden, painless vision loss due to impaired blood flow to the optic nerve. Understanding how media outlets report on such potential drug-related adverse events is critical to assess the accuracy and impact of information reaching the public, as this study addresses the gap in understanding the quality of media coverage regarding Semaglutide and NAION.

The analysis revealed that a significant portion of media reports, approximately 45%, contained inaccuracies or presented information without adequate scientific context regarding the link between Semaglutide and NAION. Specifically, 28% of articles used sensationalized headlines or language, potentially overstating the risk without providing comparative incidence rates or discussing the multifactorial nature of NAION. Conversely, only 32% of reports included direct quotes from medical experts or referenced peer-reviewed scientific literature to support their claims, indicating a lack of authoritative sourcing in many instances. > The most critical finding was that articles with sensationalized framing were 3.5 times more likely to omit crucial information about the rarity of NAION or the lack of definitive causal evidence, compared to more balanced reports (p<0.001). Furthermore, 60% of the articles failed to mention that NAION is a relatively rare condition, affecting an estimated 2.3 to 10.2 per 100,000 individuals over 50 years annually, regardless of medication use.